Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741871 | 0.86 | EGLN1 (0.49) | — | |
| SCHEMBL3744842 | 0.83 | EPHX2 (0.43) | PPARAPPARGPPARD | |
| SCHEMBL3751769 | 0.83 | EGLN1 (0.50) | TACR1MAOBHPGDALDH1A1CYP3A4 | |
| SCHEMBL3749009 | 0.82 | KMT2A (0.49) | PPARACYP1A2CYP2C19 | |
| SCHEMBL3747214 | 0.81 | CHRM4 (0.46) | MAOBPPARG | |
| SCHEMBL3743150 | 0.81 | PPARA (0.55) | PPARAHPGDKDM4EALDH1A1CYP1A2 | |
| SCHEMBL3738332 | 0.81 | MAPK14 (0.53) | PPARAHPGDPPARD | |
| SCHEMBL3746383 | 0.80 | EPHX2 (0.48) | PPARG | |
| SCHEMBL3748773 | 0.80 | EGLN1 (0.47) | PPARAHPGDALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3743964 | 0.79 | PTGDR2 (0.45) | MAOBHPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | TACR1 56/4885MLYCD 1519/4885MAOB 915/4885 |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | TACR1 56/4885MLYCD 1519/4885MAOB 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.